WO2019189115A1 - ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用並びにその製造方法 - Google Patents
ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用並びにその製造方法 Download PDFInfo
- Publication number
- WO2019189115A1 WO2019189115A1 PCT/JP2019/012744 JP2019012744W WO2019189115A1 WO 2019189115 A1 WO2019189115 A1 WO 2019189115A1 JP 2019012744 W JP2019012744 W JP 2019012744W WO 2019189115 A1 WO2019189115 A1 WO 2019189115A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- positive
- ccr6
- cell
- ccr5
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 29
- 102000009410 Chemokine receptor Human genes 0.000 title description 14
- 108050000299 Chemokine receptor Proteins 0.000 title description 14
- 108010067225 Cell Adhesion Molecules Proteins 0.000 title description 9
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 561
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims abstract description 138
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims abstract description 138
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims abstract description 132
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims abstract description 132
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims abstract description 128
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims abstract description 128
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 72
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 71
- 102100022297 Integrin alpha-X Human genes 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 239000000654 additive Substances 0.000 claims abstract description 6
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- 102100025323 Integrin alpha-1 Human genes 0.000 claims description 38
- 108010041341 Integrin alpha1 Proteins 0.000 claims description 38
- 210000005087 mononuclear cell Anatomy 0.000 claims description 36
- 102000000510 Integrin alpha3 Human genes 0.000 claims description 33
- 108010041357 Integrin alpha3 Proteins 0.000 claims description 33
- 210000001616 monocyte Anatomy 0.000 claims description 25
- 210000005259 peripheral blood Anatomy 0.000 claims description 25
- 239000011886 peripheral blood Substances 0.000 claims description 25
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 22
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 19
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 19
- 108010002350 Interleukin-2 Proteins 0.000 claims description 17
- 238000012258 culturing Methods 0.000 claims description 12
- 102000049320 CD36 Human genes 0.000 claims description 7
- 108010045374 CD36 Antigens Proteins 0.000 claims description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 7
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 7
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 7
- 230000009545 invasion Effects 0.000 claims description 7
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 6
- 102000008607 Integrin beta3 Human genes 0.000 claims description 6
- 108010020950 Integrin beta3 Proteins 0.000 claims description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 abstract description 23
- 210000002865 immune cell Anatomy 0.000 abstract description 6
- 238000002659 cell therapy Methods 0.000 abstract description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 119
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 119
- 102100025390 Integrin beta-2 Human genes 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 23
- 102100032818 Integrin alpha-4 Human genes 0.000 description 20
- 108010041012 Integrin alpha4 Proteins 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 239000002609 medium Substances 0.000 description 17
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 102100032817 Integrin alpha-5 Human genes 0.000 description 15
- 108010041014 Integrin alpha5 Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 238000000684 flow cytometry Methods 0.000 description 14
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 14
- 102000012355 Integrin beta1 Human genes 0.000 description 13
- 108010022222 Integrin beta1 Proteins 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 12
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 11
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 10
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 10
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 10
- 238000002784 cytotoxicity assay Methods 0.000 description 10
- 231100000263 cytotoxicity test Toxicity 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 230000035605 chemotaxis Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 210000004443 dendritic cell Anatomy 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 210000000713 mesentery Anatomy 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 6
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000000581 natural killer T-cell Anatomy 0.000 description 6
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 5
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000003013 erythroid precursor cell Anatomy 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 238000001215 fluorescent labelling Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 4
- 101710160107 Outer membrane protein A Proteins 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005484 gravity Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 229940022919 unituxin Drugs 0.000 description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 3
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 3
- 102100025470 Carcinoembryonic antigen-related cell adhesion molecule 8 Human genes 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 102100035716 Glycophorin-A Human genes 0.000 description 3
- 108091005250 Glycophorins Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000914320 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 8 Proteins 0.000 description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 102000003812 Interleukin-15 Human genes 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 102100030704 Interleukin-21 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102000000704 Interleukin-7 Human genes 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 229960004497 dinutuximab Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108700014844 flt3 ligand Proteins 0.000 description 3
- 238000012239 gene modification Methods 0.000 description 3
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940117681 interleukin-12 Drugs 0.000 description 3
- 108010074108 interleukin-21 Proteins 0.000 description 3
- 229940076264 interleukin-3 Drugs 0.000 description 3
- 229940100994 interleukin-7 Drugs 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 108010011491 CD11c Antigen Proteins 0.000 description 2
- 108010059108 CD18 Antigens Proteins 0.000 description 2
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000037966 cold tumor Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000585714 Homo sapiens N-myc proto-oncogene protein Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 1
- 102100037874 Intercellular adhesion molecule 4 Human genes 0.000 description 1
- 101710148793 Intercellular adhesion molecule 4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 101710159964 Tail sheath protein Proteins 0.000 description 1
- 101710168563 Tail spike protein Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960001251 denosumab Drugs 0.000 description 1
- VGRSISYREBBIAL-UHFFFAOYSA-N doronine Natural products O1C(=O)C(C(Cl)C)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN(C)CCC1C2=O VGRSISYREBBIAL-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000046457 human MYCN Human genes 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002308 idarucizumab Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000024631 kidney morphogenesis Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000007905 lung morphogenesis Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 229950007699 mogamulizumab Drugs 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229960003419 obiltoxaximab Drugs 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 229960004910 raxibacumab Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Definitions
- the present invention relates to a population of CD3 negative cells that express chemokine receptors and cell adhesion molecules and uses thereof.
- NK cells Natural killer cells
- NK cell therapy in which NK cells collected from patients themselves are proliferated and activated several hundred to several thousand times by culturing outside and returned to the patients, is attracting attention as a treatment method with relatively few side effects.
- about 1 ⁇ 10 10 mononuclear cells can be recovered from a single apheresis of normal adult peripheral blood, and the composition ratio of NK cells in peripheral blood mononuclear cells is about 7%. 10 8 NK cells are obtained.
- the patient's weight is 60 kg, it is said that 6 ⁇ 10 6 to 4.8 ⁇ 10 9 NK cells are required.
- Patent Document 1 discloses a step of preparing a cell population containing NK cells, a step of removing T cells from a cell population containing NK cells, and the remaining cells removed from 2500 IU / mL to 2813 IU / mL. And a method for amplifying NK cells, comprising a step of culturing in a medium containing IL-2.
- NK cells show cytotoxicity against tumor cell lines in vitro, but may have insufficient clinical therapeutic effects. Therefore, a culture technique for increasing the activity of NK cells has been proposed.
- U.S. Patent No. 6,056,049 describes a population of cells comprising NK cells as at least one growth factor and nicotinamide and / or other nicotine at an effective concentration, effective timing of exposure, and effective duration of exposure.
- CAR-T T cells
- NK cells T cells
- CAR-T T cells
- a large amount of effector T cells that have acquired specificity for the antigen of the target tumor are genetically modified from the peripheral blood by genetically modifying T cells that are not specific for the antigen of the target tumor. Can be created.
- CAR-T cell therapy may not be very effective for solid tumors, and one reason for this is that CAR-T cells do not reach solid tumors (Non-patent Document 1). .
- Non-patent Document 2 CAR-T cells transduced with CCR2b to express a functional chemokine receptor have been reported to have increased migration to tumors and increased antitumor activity.
- Non-Patent Document 4 investigates chemokine receptor expression in the most well-known human peripheral blood-derived CD56-positive NK cells.
- CD56 low NK cells are reported to be primarily CXCR1 / CXCR2 + and CXCR3 / CCR5 ⁇ / + and most CD56 high NK cells are reported to be CXCR1 / CXCR2 ⁇ and CXCR3 / CCR5 + . It has also been reported that it was CCR4 ⁇ and CCR6 ⁇ in both CD56 low and CD56 high NK cells (Non-patent Document 4).
- CAR-T cells may acquire desired functions such as chemotaxis in addition to antigen specificity by genetic manipulation.
- CAR-T cells are treated as gene therapy products and have strict guidelines for ensuring quality and safety. There is a problem that development takes cost and time.
- NK cells are confirmed to show cytotoxic activity against tumor cell lines in vitro, there is a problem that antitumor activity in vivo is not sufficient. This is thought to be due to the fact that NK cells are poorly chemotactic for tumors and do not infiltrate solid tumors.
- NK cells produced by these techniques are still not sufficient for clinical use. Absent. It is an object to provide immune cells having higher antitumor activity using a culture technique.
- a cell population comprising cells that are CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative.
- the CCR5 positive, CCR6 positive, CXCR3 positive and CD3 negative cells are further CD11a high expression and CD11c high expression, and the high expression is a substantial culture obtained from peripheral blood.
- the cell population according to [1] which is judged by comparison with expression in a population of NK cells that has not been subjected to.
- [3] The cell population according to [1] or [2], wherein the cells that are CCR5-positive, CCR6-positive, CXCR3-positive and CD3-negative are further Integrin ⁇ 1-positive, Integrin ⁇ 3-positive, and Integrin ⁇ 3-negative.
- [4] The cell population according to any one of [1] to [3], wherein the proportion of cells that are CCR5-positive, CCR6-positive, CXCR3-positive and CD3-negative in the cell population is 30% or more.
- [5] The cell population according to any one of [1] to [4], wherein the ratio of cells positive for any one selected from the group consisting of CD3 and CD19 is less than 5%.
- [6] The cell population according to any one of [1] to [5], wherein cells positive for any one selected from the group consisting of CD4, CD8, CD14, CD19, and CD36 are removed from the cell population.
- [7] The cell population according to any one of [1] to [6] for use in infiltration into a solid tumor.
- Cells infiltrating solid tumors that are CCR5 positive, CCR6 positive, CXCR3 positive, Integrin ⁇ 1 positive, Integrin ⁇ 3 positive, Integrin ⁇ 3 negative and CD3 negative.
- a pharmaceutical composition comprising the cell population according to any one of [1] to [7] and a pharmaceutically acceptable additive.
- the control is primary non-cultured NK cells. Negative control using isotype control antibody. Expression of cell adhesion molecules in 14 day postcultured cells of the present invention.
- the control is primary non-cultured NK cells. Expression of cell adhesion molecules in 14 day postcultured cells of the present invention.
- the control is primary non-cultured NK cells. The content rate of CD3 positive cell and CD19 positive cell in the 14-day culture cell (postcultured) of this invention.
- the control is PBMC.
- a numerical range expressed using “to” means a range including numerical values described before and after “to” as a lower limit value and an upper limit value.
- the present invention provides a cell population comprising cells that are CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative.
- Cells that are CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative are designated as “CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells” or simply “CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ ”. There is a case.
- CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ is “CCR5 + , CCR6 + , CXCR3 + Yes, and CD3 - the meaning of which is ".
- CCR5 CCR5
- CCR6 CXCR3
- Chemokines and chemokine receptors are involved in cell migration in inflammation and immune responses, and homing of hematopoietic stem cells to the bone marrow.
- a chemokine is a substance necessary for migrating leukocytes, lymphocytes, NK cells, T cells and the like to tissues, and a chemokine receptor receives chemokines on the surface of cells and transmits various signals into the cells.
- CCR5 and CCR6 are possessed by monocytes, macrophages and dendritic cells, and that CXCR3 is possessed by T cells and NK cells (NagarshethshN, et al. Nat Rev Immunol. 2017).
- CCR5 it is reported to be important for homing of injured T cells to solid tumors (Gonzaelez-Martin-A, et al. Oncoimmunology. 2012).
- CCR6 it has been reported that intratumoral induction of CCR6 along with CD103 plays a role in T cell retention at the tumor site (Franciszkiewicz K, et al. Cancer Res. 2012).
- the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cell population is characterized by high cytotoxic activity against tumor cell lines, as described later. This is a characteristic observed in known NK cells. However, no CCR6-positive NK cells have been reported so far. For example, Non-Patent Document 4 reports that CD56-positive NK cells are CCR6-negative. Thus, the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention can be distinguished from a known population of NK cells in that it is at least CCR6 positive.
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells of the present invention may be referred to as a CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ NK-like cell population, or simply a population of NK-like cells.
- known NK cells do not express T cell receptor (TCR), CD3 which is a universal marker for T cells, and large granules which do not express B cell receptor which is a membrane immunoglobulin. Although it is a sex lymphocyte and a CD16 negative population exists in part, it is usually CD16 positive in humans and CD56 positive. Whether or not it is an NK cell can be easily determined by those skilled in the art based on the expression pattern of the cell surface marker and the like.
- positive may be represented by + and negative may be represented by-.
- CCR5 positive may be represented as CCR5 + and CCR5 negative may be represented as CCR5 ⁇ .
- the positive includes a case of high expression ( high ) and a case of low expression ( low ).
- Positive, negative, high expression, and low expression can be determined based on a chart obtained by flow cytometry. The position appearing on the chart may vary depending on the voltage setting of the instrument, sensitivity setting, antibody clone used, staining conditions, dye used, etc., but those skilled in the art will recognize the cell population recognized as a group in the obtained chart. It can be drawn as appropriate so as not to be cut.
- the determination of whether the expression of the target marker is positive or negative can be made by using the isotype control antibody as a negative control.
- Isotype control antibody is an antibody that does not react with a specific antigen.
- background may be generated by non-specific binding to a protein other than the target or binding to the Fc receptor on the cell surface.
- the “cell population” refers to a group composed of a plurality of cells, for example, 1 ⁇ 10 5 cells or more.
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention can be prepared to various cell densities. For example, it can be prepared to 1 ⁇ 10 5 cells / mL or more.
- the number of cells contained in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells is preferably 1 ⁇ 10 6 cells or more, more preferably 5 ⁇ 10 6 cells or more, and even more preferably 1 ⁇ It is 10 7 cells or more.
- the number of cells included in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells can also be from 1 ⁇ 10 6 cells to 1 ⁇ 10 10 cells suitable for human administration.
- the cell density in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells is 1 ⁇ 10 5 cells / mL or more, preferably 2 ⁇ 10 5 cells / mL or more, more preferably 5 ⁇ . It is 10 5 cells / mL or more. For infusion to humans, it can be about 5 ⁇ 10 5 cells / mL.
- the upper limit value of the cell density can be set to 1 ⁇ 10 10 cells / mL or less, for example.
- the range of cell density in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells is not particularly limited, but 1 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 2 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL mL, 3 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 4 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 5 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 6 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 7 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 8 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 9 ⁇ 10 5 to 1 ⁇ 10 10 cells / mL, 1 ⁇ 10 6 to 1 ⁇ 10 10 cells / mL, 1 ⁇ 10 7 ⁇ 1 ⁇ 10 10 cells / mL, 1 ⁇ 10 8 ⁇ 1 ⁇ 10 10 cells
- the cell density in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells can also be 1 ⁇ 10 6 to 1 ⁇ 10 8 cells / mL suitable for culture and cryopreservation, and administration to humans 1 ⁇ 10 5 to 1 ⁇ 10 9 cells / mL suitable for the above.
- the proportion of cells that are CCR5 positive, CCR6 positive, CXCR3 positive and CD3 negative in the cell population may be higher, 55% or more, 60% or more, 65% or more, 70% or more, 75 % Or more, 80% or more, 85% or more, 90% or more, or 95% or more.
- the degree of expression of the target marker (whether it is low expression or high expression) can be determined by comparison with the results of the control cell population measured under the same conditions.
- An example of a population of control cells is a population of NK cells obtained from peripheral blood, such as primary NK described in the examples herein, that has not undergone substantial culture.
- the degree of CCR6 expression in a population of cells cultured for a certain period of time was determined using flow cytometry, and the amount of CCR6 expression in that cell population was determined from the population of NK cells that had not undergone substantial culture obtained from peripheral blood (control). It is known that the expression is negative for CCR6.
- the expression of CCR6 in the population of cells cultured for a certain period is bimodal, and the expression level is higher than that of the control in both peaks, it can be determined that there is low expression and high expression.
- the cells included in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention can be either CCR6 high expressing or CCR6 low expressing.
- CCR5 + / CCR6 + / CXCR3 + / CD3 provided by the present invention - the population of cells, CCR6 a high expressing CCR5 + / CCR6 + / CXCR3 + / CD3 - population of cells, and CCR6 low expressing CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cell populations may be included. Cell populations containing both are bimodal when analyzed for CCR6 by flow cytometry.
- the cells included in the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cell population provided by the present invention can be CCR5 positive and CXCR3 positive.
- CCR5 high expression and CXCR3 high expression may be present. High expression can be determined by comparison with the expression of CCR5 and CXCR3 in myeloid cells such as macrophages and MDSCs.
- the cells included in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention can be any one selected from the group consisting of CXCR1 and CXCR2.
- Cells included in the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cell population provided by the present invention are negative or very low in expression, either selected from the group consisting of CCR2, CCR4 and CXCR4 Can be sex.
- the cell population containing cells that are CCR5-positive, CCR6-positive, CXCR3-positive and CD3-negative provided in the present invention can be obtained by the method for producing a population of NK-like cells described later.
- the method for producing a population of NK-like cells includes a step of removing any one selected from the group consisting of monocytes and B cells from the population of primary mononuclear cells, but the group consisting of monocytes and B cells. Any removal selected from may not be necessary.
- the cells contained in the cell population provided by the present invention can be naturally derived.
- a cell derived from nature is a non-genetically recombinant cell, a cell not derived from a foreign transgenic animal or a transformed cell, or a cell that has not been prepared by cell fusion technology. Although it represents, it does not mean the naturally occurring cell itself, but means a cell produced by a culture technique.
- Non-genetically recombinant cells in the present invention means cells that are not produced using mononuclear cells isolated from the blood of animals that have been artificially altered in genetic information using genetic modification techniques. To do.
- a cell not derived from a foreign gene-transferred animal or a transformed cell means a cell prepared without going through a step of introducing a foreign gene into an organism or cell.
- a cell that has not been created by cell fusion technology means that it is neither a cell produced by cell fusion nor a cell derived from it, for example, it does not regulate cell surface antigen expression by cell fusion or the like. .
- CD11c is a cell adhesion molecule also known as integrin ⁇ X.
- CD11c is known to be expressed in monocytes, macrophages, granulocytes, and myeloid dendritic cells. CD11c is known to bind to CD18 and participate in cell adhesion and the like.
- the degree of CD11c expression in a population of cells cultured for a certain period of time was determined using flow cytometry, and the expression level of CD11c in the cell population was determined from the population of NK cells that had not undergone substantial culture obtained from peripheral blood (control). It is known that CD11c is low-expressing. When the expression level of CD11c in the population of cells cultured for a certain period of time is higher than that of the control, it can be determined that there is high expression.
- a cell population comprising CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative cells provided by the present invention is such that the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells are highly expressed in CD11a / CD18.
- CD11a / CD18 also known as LFA-1, is distributed in T lymphocytes, interacts with ICAM-1 or ICAM-4, is involved in leukocyte adhesion and chemotaxis, and induces immune tolerance are known.
- the degree of expression of CD11a / CD18 in a population of cells cultured for a certain period of time is determined by using flow cytometry, and the amount of CD11a / CD18 expression in the cell population is determined from NK cells that have not been subjected to substantial culture obtained from peripheral blood. In comparison with the CD11a / CD18 expression level in the control population (control. CD11a / CD18 is known to have low expression).
- control. CD11a / CD18 is known to have low expression.
- a cell population comprising CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative cells provided by the present invention the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells further comprises Integrin ⁇ 1, Integrin ⁇ 3, Integrin Any one selected from the group consisting of ⁇ 4, Integrin ⁇ 5, ICAM-1, and Integrin ⁇ 1 can be highly expressed.
- a population of NK cells obtained from peripheral blood that has not undergone substantial culture (control. Integrin ⁇ 1, Integrin ⁇ 3, Integrin ⁇ 4, Integrin ⁇ 5, ICAM-1, Integrin ⁇ 1 are known to be negative or low-expressing. It can be determined that there is high expression.
- Integrin ⁇ 4 / Integrin ⁇ 1 is also called VLA-4, and is known to interact with fibronectin, VCAM-1, etc., and participate in migration of lymphocytes, monocytes, and eosinophils to inflammatory sites. .
- Integrin ⁇ 1 / Integrin ⁇ 1 is also called VLA-1 and is known to be distributed in a wide range of cells and interact with collagen and laminin to participate in neurite outgrowth and lymphocyte infiltration.
- Integrin ⁇ 3 / Integrin ⁇ 1, also known as VLA-3 is distributed in a wide range of cells and interacts with laminin-5, TSP, uPAR, and is involved in kidney and lung morphogenesis, cancer invasion and metastasis It has been known.
- a cell population comprising CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative cells provided by the present invention is obtained from the CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative cells, and Integrin ⁇ 1 It can be positive, Integrin ⁇ 3 positive and Integrin ⁇ 3 negative.
- Integrin ( ⁇ 1, - ⁇ 3, and - ⁇ 3 are all negative in NK cells (primary NK) before culture.
- NK cells after 2 weeks of culture are all positive for Integrin ⁇ 1, - ⁇ 3 and - ⁇ 3 (Maenpaa et al., Int. J.
- Cells that are CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative in the cell population provided by the present invention are at least Integrin ⁇ 1 positive, Integrin ⁇ 3 positive and Integrin ⁇ 3 negative from conventional NK cell cultures. It is different in that.
- a cell population comprising CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative cells provided by the present invention has a high expression of the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells as Integrin ⁇ 4 / Integrin ⁇ 1.
- a cell population comprising CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative cells provided by the present invention has a high expression of the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells as Integrin ⁇ 1 / Integrin ⁇ 1.
- a cell population comprising CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative cells provided by the present invention has a high expression of Integrin ⁇ 3 / Integrin ⁇ 1 in the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells. Can be.
- the populations of NK-like cells provided by the present invention are CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ , CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c high , CCR5 + / CCR6 + / CXCR3 + / CD3 - / CD11c high / CD11a high, CCR5 + / CCR6 + / CXCR3 + / CD3 - / CD11c high / CD11a high / CD18 high, CCR5 + / CCR6 + / CXCR3 + / CD3 - / CD11c high / CD11a high / CD18 high / Integrin ⁇ 1 high, CCR5 + / CCR6 + / CXCR3 + / CD3 - / CD11c high / CD11a high / CD18 high / Integrin ⁇ 1 high, CCR5 + / CCR6
- the specific NK-like cells included in the population of NK-like cells provided by the present invention can be positive for any one or both selected from the group consisting of CD16 and CD56.
- CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells included in the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention may be any one selected from the group consisting of CD16 and CD56.
- One or both can be positive.
- the specific NK-like cells included in the population of NK-like cells provided by the present invention can be negative in any one or both selected from the group consisting of CXCR1 and CXCR4.
- the proportion of cells positive for any one selected from the group consisting of CD3 and CD19 can be less than 10%.
- the ratio of these cells in the cell population can be analyzed by flow cytometry.
- the proportion of cells positive in any one selected from the group consisting of CD3 and CD19 in the cell population is preferably less than 5%, more preferably less than 2%. This is because the higher the ratio of cells that are CCR5-positive, CCR6-positive, CXCR3-positive and CD3-negative in the cell population is considered to have higher tumor cytotoxic activity.
- the population of NK-like cells provided by the present invention can have increased chemotaxis to the tumor site. Also, the population of NK-like cells provided by the present invention can invade a tumor mass. Infiltration into a tumor mass means a state in which cells (for example, immune cells) have entered the tumor mass.
- Chemotaxis to the tumor site can be evaluated by a cell migration assay.
- the cell migration assay can be performed by the transwell method or the like in the presence of tumor cells.
- the population of NK-like cells provided by the present invention can have increased chemotaxis to a tumor site compared to a population of NK cells obtained from peripheral blood and not subjected to substantial culture.
- the chemokine receptors CCR5, CXCR3 and High expression of CCR6 is thought to be associated with increased chemotaxis to the tumor site.
- Invasion into a tumor mass can be evaluated by a cytotoxicity assay against spheroids prepared from a tumor cell line.
- a spheroid is a cell aggregate obtained by three-dimensional cell culture, and an interaction between cells and an extracellular matrix are developed.
- tight junctions may exist at the outer edge, and the inside is in a low oxygen state and low pH, so that metabolism and functional activity are considered to be closer to tissues in the living body.
- Tumor spheroids are expected as next-generation in vitro experimental models for drug development (Hirschhaeuser F. et al., J Biotechnol. 2010 Jul 1; 148 (1): 3-15; Xiang X.
- NK-like cells provided by the present invention can be fluorescently labeled, and the transition into the spheroids can be observed.
- NK cells obtained from peripheral blood and not subjected to substantial culture do not infiltrate spheroids, NK-like cells provided by the present invention can infiltrate spheroids.
- the cell adhesion molecule LFA-1 / VLA-4 is thought to be important for invasion of solid tumors (Sackstein®, et al. Lab Invest. 2017). According to the study by the present inventors, the expression of cell adhesion molecules was observed in the population of NK-like cells provided by the present invention as compared to the population of NK cells obtained from peripheral blood and not subjected to substantial culture. High is thought to be related to spheroid infiltration.
- a spheroid formed from an IMR32 cell line human MYCN amplified neuroblastoma cell line
- NK cells obtained from peripheral blood and not subjected to substantial culture are But did not infiltrate.
- an anti-GD2 antibody Unituxin (registered trademark) is capable of damaging the IMR32 cell line alone (Doronin et al., BMC Cancer 2014, 14: 295), but against IMR32 that formed spheroids. Under the microscope, no morphological changes were observed as cells were damaged.
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention was infiltrated with spheroids, and spheroids began to collapse after 12 hours from the start of the assay.
- the cytotoxic activity against spheroids was very high in the population of NK-like cells provided by the present invention compared to NK cells obtained from peripheral blood and not subjected to substantial culture.
- the cytotoxic activity against spheroids was not significantly different between both the NK-like cell population provided by the present invention and the system using the antibody together with the system not using the antibody.
- the population of NK-like cells provided by the present invention can exhibit high cytotoxic activity as described above.
- the cytotoxic activity refers to the ability of the target cell (effector cell, E) to lyse the target cell (T) unless otherwise specified.
- the cytotoxic activity can be expressed as a percentage (%) of target cells that have been killed by effector cells, and is determined by the following formula. (Cell death when co-cultured with effector cells-natural cell death (negative control)) / (maximum cell death (positive control)-natural cell death (negative control)) x 100
- the target cells are spheroids of IMR32 cell line, glioma, breast cancer, colon cancer, ovarian cancer Spheroids prepared from tumor cell lines such as prostate cancer can be used, but are not limited thereto.
- the size of the spheroid that can be used can be about 150 to 500 ⁇ m in diameter, but is not limited thereto.
- Effector cells and target cells, live cells and dead cells can be distinguished and quantified by reagents such as antibodies labeled with radioactive substances, fluorescent dyes and the like.
- the cytotoxic activity when NK-like cells are used as effector cells can be measured, for example, by targeting spheroids of the IMR32 cell line, and the incubation time is 8 to 48 hours, preferably 12 to 24 hours.
- the present invention provides CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative cells infiltrating solid tumors.
- conventional NK cells are thought not to be successful against solid tumors
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells provided by the present invention infiltrate solid tumors and Can be injured.
- Invasion into solid tumors was observed when CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells migrated to the inside of the tumor mass (spheroid), and the shape of the tumor mass changed over time. It can be judged by collapse. Tumor cell damage can be confirmed by an increase in the number of dead cells by flow cytometry.
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ NK-like cells provided by the present invention can have a therapeutic effect on solid tumors in vivo.
- the therapeutic effect on solid tumors in vivo can be evaluated by transplanting human tumor cells into animals such as immunodeficient mice and observing their progress.
- the prophylactic effect may be evaluated by administering a population of NK-like cells simultaneously with transplantation.
- the therapeutic effect may be evaluated by confirming the growth of the tumor for about 5 days and then administering NK-like cells in groups. Evaluation can be carried out by dissecting euthanized mice and observing fluorescently labeled tumor cells.
- In vivo treatment regimes may be administered to animals in single or multiple doses. Regardless of whether it is an independent single dose or continuous infusion, a population of NK-like cells will have an initial candidate dose of 1 ⁇ 10 5 cells to 1 ⁇ 10 8 cells per kg. IL-2 can be administered with a population of NK-like cells. IL-2 can be administered to maintain the activity of the administered NK-like cells in the animal. The initial candidate dose of IL-2 is 1,000 to 10,000 IU per animal. In vivo treatment regimes can employ intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration by any suitable means. Evaluation of the therapeutic effect can be performed by observing fluorescently labeled tumor cells and / or calculating the number of pixels in the fluorescence positive region.
- the population of NK-like cells provided by the present invention is compared to SKOV3 cells (human ovarian cancer cells) transplanted into immunodeficient mice compared to a population of NK cells obtained from peripheral blood and not subjected to substantial culture. The number of stocks can be reduced.
- the population of NK-like cells provided by the present invention can almost eliminate SKOV3 cells (human ovarian cancer cell line) transplanted into immunodeficient mice.
- SKOV3 cells transplanted into immunodeficient mice have been confirmed to form tumor nodules when untreated, but in mice treated with a population of NK-like cells provided by the present invention, SKOV3 cells were almost extinct and no tumor nodules were observed.
- the population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ NK-like cells provided by the present invention is a solid tumor. It can be said that it can invade and damage tumor cells.
- the present invention is selected from the group consisting of a step of preparing a primary mononuclear cell population, a step of removing CD3-positive cells from the primary mononuclear cell population, and a group consisting of monocytes and B cells from the primary mononuclear cell population. And a step of culturing the CD3 positive cells and the remaining cell population from which any one selected from the group consisting of monocytes and B cells has been removed in a medium containing IL-2, A method for producing a population of cells that are CCR5 positive, CCR6 positive and CXCR3 positive and CD3 negative.
- the primary mononuclear cell population can be obtained by a step of separating mononuclear cells from blood cells collected from a subject.
- the blood cell may be taken from any selected from the group consisting of peripheral blood, umbilical cord blood, bone marrow and lymph nodes. Blood cells may be collected from peripheral blood by apheresis.
- the primary mononuclear cell population prior to culture can be free of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells.
- the primary mononuclear cell population includes hematopoietic stem cells derived from any stem cell selected from the group consisting of embryonic stem cells, adult stem cells, and induced pluripotent stem (iPS) cells, and cord blood.
- hematopoietic stem cells derived from any stem cell selected from the group consisting of embryonic stem cells, adult stem cells, and induced pluripotent stem (iPS) cells and cord blood.
- iPS induced pluripotent stem
- a subject who is a donor of a primary mononuclear cell population may be derived from the recipient patient himself, a close relative of the patient, or an unrelated patient.
- the test subject may be a healthy person or a patient suffering from a disease.
- the NK-like cells provided by the present invention may be derived from a donor in which the recipient's major histocompatibility antigen (MHC) and the killer immunoglobulin-like receptor (KIR) are inconsistent. is there.
- T cells and / or NKT cells may be removed by the step of removing CD3-positive cells from the primary mononuclear cell population.
- the removal of T cells may be achieved by a step of removing one or two selected from CD4 positive cells and CD8 positive cells in addition to CD3 positive cells.
- removal of monocytes includes CD14 positive cells, CD36 positive cells, And may be achieved by removing one, two, or three cells selected from HLA-DR positive cells.
- Removal of B cells may be achieved by removing one or two cells selected from CD19 positive cells and CD20 positive cells.
- the removal of CD3 positive cells and any removal selected from the group consisting of monocytes and B cells may be performed simultaneously or in separate steps.
- Monocyte removal and B cell removal may be performed simultaneously or in separate steps.
- the method for producing NK-like cells of the present invention may include a step of removing any one selected from the group consisting of dendritic cells, granulocytes, and macrophages from the primary mononuclear cell population. Any removal selected from the group consisting of dendritic cells, granulocytes and macrophages can be performed by removing one, two or three types of cells selected from CD66b positive cells, CD123 positive cells and HLA-DR positive cells. It may be carried out depending on the removing step.
- the method for producing NK-like cells of the present invention may include a step of removing hematopoietic progenitor cells from a primary mononuclear cell population.
- the step of removing hematopoietic progenitor cells may be accomplished by a step of removing CD34 positive cells.
- the method for producing NK-like cells of the present invention may include a step of removing erythrocytes and erythroid progenitor cells from a primary mononuclear cell population.
- the step of removing erythrocytes and erythroid progenitor cells may be achieved by a step of removing glycophorin A positive cells.
- the primary mononuclear cell population can be prepared using various procedures known to those skilled in the art. For example, specific gravity centrifugation can be used to recover mononuclear cells from blood such as umbilical cord blood and peripheral blood. Furthermore, the primary mononuclear cell population, and the remaining cell population from which any one selected from the group consisting of monocytes and B cells has been removed from the primary mononuclear cell population are specific for cell surface markers. Can be isolated and identified using a cell sorter or flow cytometer. In addition, the remaining cell population from which any one selected from the group consisting of CD3 positive cells and monocytes and B cells was removed from the primary mononuclear cell population was Dynabeads (trademark manufactured by Dynal, sold by Invitrogen). ) And Milteny Biotech's CliniMACS TM, but not limited thereto, may be prepared by separating and removing cells expressing a specific cell surface antigen.
- T cells, NKT cells, monocytes, B cells, dendritic cells, granulocytes, macrophages, erythrocytes, erythroid progenitor cells or hematopoietic progenitor cells are used for specific T cells, NKT cells.
- Monocytes, B cells, dendritic cells, granulocytes, macrophages, erythrocytes, erythroid progenitor cells or hematopoietic progenitor cells may be selectively injured or killed.
- the step of removing CD3 positive cells from the primary mononuclear cell population and the step of removing any one selected from the group consisting of monocytes and B cells from the primary mononuclear cell population include CD3 positive cells, single cells It may be a step of removing both spheres and B cells.
- the step of removing CD3-positive cells, monocytes and B cells is from the group consisting of other cell types, eg, erythrocytes, erythroid progenitor cells, hematopoietic progenitor cells, dendritic cells, granulocytes, macrophages and NKT cells. It may be a step of removing any selected together with CD3 positive cells, monocytes and B cells.
- a cell culture medium used for culturing the remaining cell population from which any one selected from the group consisting of CD3 positive cells and monocytes and B cells has been removed from the primary mononuclear cell population is KBM501 medium (Kohjin Bio Inc. Contains 1,750 JRU / ml of IL-2, for human NK cell primary culture, CellGro SCGM medium (Cergenics, Iwai Chemical Co., Ltd.), X-VIVO15 medium (Lonza, Takara Bio Inc.) Cosmedium 008 (Cosmo Bio. Contains IL-2 at 1,750 JRU / ml.
- Interleukin-2 may be added to the medium at a concentration that can achieve the object of the present invention.
- the concentration of IL-2 can be from 100 IU / mL to 5000 IU / mL.
- the concentration of IL-2 may be between 2500 IU / mL and 2813 IU / mL.
- IL-2 preferably has a human amino acid sequence and, for safety, is preferably produced by recombinant DNA technology.
- the concentration of IL-2 may be indicated in national standard units (JRU) and international units (IU). One IU is about 0.622 JRU.
- the medium may be supplemented with autologous serum of the subject, human AB serum available from BioWhittaker and others, and donated human serum albumin available from the Japanese Red Cross.
- Autologous serum and human type AB serum are preferably added at a concentration of 1 to 10%
- donated human serum albumin is preferably added at a concentration of 1 to 10%.
- the serum contained in the medium can be human serum or non-human animal serum, but is preferably human serum albumin.
- platelet extracts such as UltraGro TM ) available from Corefront and others can be used. The platelet extract is preferably added at a concentration of 1 to 10%.
- the medium may contain appropriate proteins, cytokines, antibodies, compounds and other components, provided that the amplification effect of the population of NK-like cells is not impaired.
- Cytokines include interleukin 3 (IL-3), interleukin 7 (IL-7), interleukin 12 (IL-12), interleukin-15 (IL-15), interleukin-21 (IL-21), It may be selected from the group consisting of stem cell factor (SCF) and FMS-like tyrosine kinase 3 ligand (Flt3L).
- IL-3, IL-7, IL-12, IL-15, IL-21, SCF and Flt3L preferably have human amino acid sequences, and for safety, are preferably produced by recombinant DNA technology.
- the medium is preferably a serum-free medium.
- the serum-free medium preferably contains serum albumin, transferrin, and insulin.
- Serum-free media for culturing lymphocytes have been developed and marketed and can be used in the present invention.
- One preferred example of the serum-free medium is a basal medium supplemented with CTS Immune Cell SR (Thermo Fisher Scientific), which is commercially available as a composition that supports the proliferation of human T cells.
- the serum albumin contained in the medium can be human serum albumin or non-human animal serum albumin, but is preferably human serum albumin.
- the culture can be performed by feeder-less culture. This is because when feeder cells are used for the culture, there is a risk of infection in the produced cell population.
- Medium replacement, addition or supplementation may be performed at any time after the start of culture, provided that the desired number of NK-like cells is obtained, but is preferably every 3-5 days.
- the culture vessel used for the culture includes, but is not limited to, a commercially available dish, a culture bag, a flask, a plate, and a multiwell plate.
- the culture conditions are not particularly limited as long as the amplification effect of the NK-like cells is not impaired, but culture conditions under 37 ° C., 5% CO 2 and saturated water vapor atmosphere are common.
- the culture period is not particularly limited, provided that the cells in the population of NK-like cells are amplified to the desired number of cells.
- the culture period may vary depending on the culture conditions. If the culture conditions are 37 ° C., 5% CO 2 and saturated water vapor atmosphere, the culture period can be 4 to 15 days. The upper limit of the culture period can be around 21 days.
- the predetermined population of NK-like cells obtained by the culture can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells.
- the predetermined population of NK-like cells obtained by the culture can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + cells.
- the predetermined population of NK-like cells obtained by culturing can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + cells.
- the predetermined population of NK-like cells obtained by the culture can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + cells.
- the predetermined population of NK-like cells obtained by the culture can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + cells.
- the predetermined population of NK-like cells obtained by culture can be a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + / Integrin ⁇ 3 + cells .
- a predetermined population of NK-like cells obtained by culture is a population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + / Integrin ⁇ 3 + / Integrin ⁇ 4 + Can be.
- the predetermined population of NK-like cells obtained by the culture is CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + / Integrin ⁇ 3 + / Integrin ⁇ 4 + / Integrin ⁇ 5 + It can be a population of cells.
- the predetermined population of NK-like cells obtained by the culture is CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + / Integrin ⁇ 3 + / Integrin ⁇ 4 + / Integrin ⁇ 5 + It can be a population of / ICAM-1 + cells.
- the predetermined population of NK-like cells obtained by the culture is CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / CD11c + / CD11a + / CD18 + / Integrin ⁇ 1 + / Integrin ⁇ 3 + / Integrin ⁇ 4 + / Integrin ⁇ 5 + It can be a population of / ICAM-1 + / Integrin ⁇ 1 + cells.
- the predetermined population of NK-like cells obtained by the culture is CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / Integrin ⁇ 1 high , CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ / Integrin ⁇ 1 high / Integrin ⁇ 3 high , CCR5 + / CCR6 + / CXCR3 + / CD3 - / Integrin ⁇ 1 high / Integrin ⁇ 3 high / Integrin ⁇ 4 high, CCR5 + / CCR6 + / CXCR3 + / CD3 - / Integrin ⁇ 1 high / Integrin ⁇ 3 high / Integrin ⁇ 4 high / Integrin ⁇ 5 high, CCR5 + / CCR6 + / CXCR3 + / CD3 - / Integrin ⁇ 1 high / Integrin ⁇ 3 high / Integrin ⁇ 4 high / Integrin ⁇ 5 high, CCR5 +
- the CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ cells contained in these populations of NK-like cells can be positive for either or both selected from the group consisting of CD16 and CD56.
- the specific NK-like cells contained in the population of these NK-like cells can be negative for either one or both selected from the group consisting of CXCR1 and CXCR4.
- the proportion of cells expressing each surface antigen in the cell population (positive) Rate). For example, in arithmetic interpretation, if 50% of the cells expressing surface antigen A are present in all cells and 50% of the cells expressing surface antigen B are 50% of all cells in the cell population, surface antigens A and B May be 0% of all cells. However, if 90% of all cells express surface antigen A and 90% of all cells express surface antigen B, 0% of all cells expressing both surface antigens A and B. There is no possibility of%.
- Integrin ⁇ 1-positive cells and Integrin ⁇ 3-positive cells are also found to be present in 91.0% and 75.3%, respectively, in the cell population obtained by culture. This result shows that there are cells in which CCR5, CCR6, CXCR3, IntegrinIntegr ⁇ 1 and Integrin ⁇ 3 are copositive in the cell population.
- the purity of the specific NK-like cells in a predetermined population of NK-like cells obtained by culturing is 30% or more. It may be. Since the therapeutic effect is considered to be higher as the purity of a specific NK-like cell population is higher, the purity is preferably 30% or more, 35% or more, 40% or more, 45% or more, or 50% or more. .
- the purity of the specific NK-like cell population may be higher, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% % Or more, or 95% or more.
- the predetermined population of NK-like cells obtained by culture includes cells that are CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative, and is selected from the group consisting of CD3, CD4, CD8, CD14, CD19 and CD36.
- the predetermined population of NK-like cells obtained by culture includes cells that are CCR5-positive, CCR6-positive and CXCR3-positive and CD3-negative, and is from the group consisting of CD3, CD4, CD8, CD14, CD19, and CD36.
- the percentage of cells that are positive for any selected can be less than 10%. The ratio of these cells can be analyzed by flow cytometry.
- the proportion of cells positive in any one selected from the group consisting of CD3, CD4, CD8, CD14, CD19 and CD36 in the cell population is preferably less than 5%, more preferably less than 2%. This is because the higher the ratio of cells that are CCR5-positive, CCR6-positive, CXCR3-positive and CD3-negative in the cell population is considered to have higher tumor cytotoxic activity.
- the population of NK-like cells obtained by the production method of the present invention is enriched NK-like in the sense that the desired CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ NK-like cell population is preferentially cultured and amplified. It can be said that it is a group of cells.
- a predetermined population of NK-like cells obtained by culturing may contain NK cell precursors, T cells, NKT cells, hematopoietic progenitor cells and the like in addition to the target NK-like cells.
- the target NK-like cells or population thereof may be selected using, for example, specific gravity centrifugation, immunomagnetic beads, FACS, flow cytometry, or the like.
- a target NK-like cell population may be selectively separated using an anti-KIR2DL5 antibody, an anti-NKp46 antibody, an anti-NKp30 antibody, an anti-NKG2D antibody, or the like.
- the antibody may be a monoclonal antibody or a polyclonal antibody.
- the selection of a target NK-like cell population may be performed by selectively removing T cells, NKT cells, hematopoietic progenitor cells and other cells.
- the present invention provides a pharmaceutical composition comprising a population of NK-like cells and a pharmaceutically acceptable additive.
- pharmaceutically acceptable additives include isotonic agents, pH adjusters, buffers, stabilizers, cryoprotectants, antibiotics and the like. Specific examples include water, ethanol, sodium chloride, glucose, albumin and the like.
- the population of NK-like cells contained in the pharmaceutical composition of the present invention is preferably the above-mentioned population of CCR5 + / CCR6 + / CXCR3 + / CD3 ⁇ NK-like cells provided by the present invention.
- the cell population contained in the pharmaceutical composition of the present invention is preferably a population of NK-like cells with high tumor cytotoxic activity, and more preferably a population of NK-like cells that infiltrate solid tumors.
- the pharmaceutical composition of the present invention may be administered to a patient having an HLA genotype different from that of NK-like cells produced by the production method of the present invention.
- the pharmaceutical composition is typically in the form of NK-like cells suspended in a solution.
- a solution for suspending NK-like cells for example, a protective solution for freezing containing DMSO, physiological saline, phosphate buffered saline (PBS), medium, serum and the like are generally used.
- the solution may contain pharmaceutically acceptable carriers as pharmaceuticals and quasi drugs.
- the pharmaceutical composition of the present invention may be used for treating infectious diseases or cancer.
- the pharmaceutical composition of the present invention can also be applied to the treatment of various diseases sensitive to NK-like cells.
- the pharmaceutical composition of the present invention can also be applied to the prevention of various diseases sensitive to NK-like cells.
- Diseases include, but are not limited to, oral cancer, gallbladder cancer, bile duct cancer, lung cancer, liver cancer, colon cancer, kidney cancer, bladder cancer, leukemia, and infections caused by viruses, bacteria, and the like.
- the cell therapy of the present invention may be carried out alone or in combination with surgery, chemotherapy, radiation therapy, antibody drugs, and the like.
- NK-like cells may be administered to, for example, veins, arteries, subcutaneous, intraperitoneally, and the like.
- the pharmaceutical composition of the present invention can be administered together with an IL-2 preparation.
- the IL-2 preparation may be a recombinant type, and can be teseleukin (genetical recombination).
- the pharmaceutical composition of the present invention can be expected to have a high therapeutic effect without necessarily being used in combination with an antibody drug.
- antibody-dependent cellular cytotoxicity As one of the known mechanisms of cytotoxicity by NK cells, antibody-dependent cellular cytotoxicity (Antibody dependent cellular cytotoxicity, ADCC) is known.
- NK cells have an Fc receptor (CD16) on their cell surface, and ADCC is a mechanism in which NK cells bind to an antibody bound to a target cell via the Fc receptor and damage the target cell.
- CD16 Fc receptor
- ADCC is a mechanism in which NK cells bind to an antibody bound to a target cell via the Fc receptor and damage the target cell.
- a known NK cell and an antibody having a high affinity for CD16 may be used in combination.
- the population of NK-like cells of the present invention has a high cytotoxic activity without using an antibody in combination.
- the population of NK-like cells contained in the pharmaceutical composition of the present invention has increased chemotaxis to the tumor site compared to a population of NK cells obtained from peripheral blood and not subjected to substantial culture, Has been found to infiltrate the tumor mass.
- high cytotoxic activity was shown in both the system using the NK-like cell population and the antibody and the system using the NK-like cell population alone, but there was no significant difference. This indicates that NK-like cells have high cytotoxic activity against tumor cells without inducing ADCC activity.
- the pharmaceutical composition of the present invention may be used in combination with an antibody drug.
- antibodies that can be used in combination with the pharmaceutical compositions of the present invention, ibritumomabtiuxetan, iodine131, catumaxomab, blinatumomab, muromonab-CD3, abciximab, rituximab, basiliximab, infliximab, cetuximab, brentuximab, siltuximab, dinutuximab, obiltoxaximab, daclizumab, palivizumab, trastuzumab, gemtumumab, alemtuzumab, omalizumab, efalizumab, bevacizumab, natalizumab, tocilizumab, ranibizumab, eculizum b, certolizumabpegol, mogamulizumab, pertu
- the antibody that can be used in combination with the pharmaceutical composition of the present invention preferably has a high affinity for CD16.
- at least part of the antibody may be bound to NK-like cells.
- the production of the pharmaceutical composition of the present invention is performed under conditions (good manufacturing practices, GMP) conforming to the production control and quality control rules of pharmaceuticals and quasi-drugs, and the standards for manufacturing management and quality control of products such as regenerative medicine (Good Gene) , Cellular, and Tissue-based Products Manufacturing Practice, GCTP).
- GMP good manufacturing practices
- GCTP regenerative medicine
- the present invention provides the use of a population of NK-like cells in the manufacture of a medicament for use in the treatment of solid tumors.
- the present invention provides a population of NK-like cells for use in solid tumor invasion.
- the present invention provides a method for the treatment and prevention of a solid tumor in a patient comprising the step of administering to the patient a therapeutically effective amount of a population of NK-like cells. Since the population of NK-like cells of the present invention can damage tumor cells of solid tumors, it is useful for the treatment and prevention of solid tumors in patients.
- the present invention provides kits for use in the above therapeutic or research applications.
- the kit can include one or more containers such as bags, vials and tubes.
- the container can comprise a pharmaceutical composition comprising a cell population provided by the present invention, optionally with pharmaceutically acceptable additives.
- the kit can include a container containing a population of cells provided by the present invention in combination with another drug or antibody drug.
- the kit optionally includes a cell population with a label or instructions for a therapeutic or research application as described herein.
- PBMC peripheral blood mononuclear cells
- CD3 positive cells were removed from PBMC using 5 ⁇ L of CliniMACS CD3 (Miltenyi Biotech, catalog number 130-017-601) per 1 ⁇ 10 7 cells (collected cells are expressed as “Primary NK”) ) And the remaining cells were cultured.
- chemokine receptor used the cells of the present invention after 14 days of culture and “Primary NK”, which was a cell collected before the culture, as a control.
- the analysis was performed by flow cytometry, and a BD LSRFortessa TM cell analyzer (BD Bioscience) was used. Fluorescent labeling of cells cultured for 14 days and Primary NK is carried out at 2-8 ° C in an antibody solution in which each antibody shown in Table 1 is suspended in PBS (Wako Pure Chemical Industries) at a final concentration of 1 ⁇ g / mL. This was done by incubating in the dark for 30 minutes.
- FIG. 1A The results are shown in FIG. 1A.
- MDSC Myeloid-derived suppressor cells
- Treg an immunosuppressive cell population
- the cells of the present invention are considered to have the same chemotaxis as those described above, it is assumed that cold tumors can be efficiently infiltrated and injured by immunotherapy which is considered to be extremely difficult to achieve. .
- FIGS. 1C and D The results are shown in FIGS. 1C and D.
- the cells of the present invention cultured for 14 days strongly expressed the cell adhesion molecules ICAM1, Integrin ⁇ 1, LFA-1 ⁇ , Integrin ⁇ 2, Integrin ⁇ 3, Integrin ⁇ X, Integrin ⁇ 2, PECAM-1, Integrin ⁇ 5, Integrin ⁇ 4 and Integrin ⁇ 1.
- Invasion of tumor tissue requires cell-cell adhesion or adhesion to the extracellular matrix at multiple points, such as leakage to the outside of the blood vessel, passage of stroma, adhesion to the tumor cell mass, and invasion.
- the cells obtained in the present invention are considered to have an adhesion molecule expression pattern that enables any of them.
- Example 2 ⁇ Content of CD3-positive cells and CD19-positive cells >>
- the cells of the present invention cultured for 14 days were used as in Example 1, and PBMC was used as a control.
- the antibodies used for fluorescent labeling are PE-labeled anti-human CD3 antibody (Biolegend, 300408) and PerCP-Cy5.5-labeled anti-human CD19 antibody (Biolegend, 302230).
- the fluorescent labeling was performed in the same procedure as in Example 1.
- the results are shown in FIG. CD3 positive cells contained in the cells of the present invention cultured for 14 days were 0.025%, and CD19 positive cells were 0.28%.
- CD3 positive cells contained in PBMC not cultured were 64.7% and CD19 positive cells were 8.57%.
- IMR32 cells human MYCN-amplified neuroblastoma cell line
- RPMI 50% FBS
- EZ-Bind Shut II registered trademark
- IMR32 spheroids were transferred to a 384-well microplate (film bottom, for high-content imaging) (CORNING, Cat. 4518) using a 200 ⁇ L chip, and each cell was incubated at 37 ° C for 1-2 hours. Glued to the bottom.
- the cells of the present invention used for the target cell cytotoxicity assay were induced by the method described in Example 1.
- a population of NK cells (referred to as primary NK) used as a control was treated with EasySep TM Human NK Cell Enrichment Kit (STEMCELL Technologies, Cat. 19055) by treating PBMC separated from the peripheral blood of healthy volunteers by specific gravity centrifugation. Released.
- the cells of the present invention and primary NK were stained with PKH26 Red fluorescent cell linker kit (for general cell membrane) (SIGMA-ALDOLICH, Cat. PKH26GL, hereinafter PKH26).
- PKH26-stained cells of the present invention have entered the IMR32 spheroid.
- the tumor mass begins to collapse including the center after 12 hours from the start of the assay.
- PKH26-stained primary NK gathers on the surface of IMR32 spheroid, but does not penetrate inside.
- the anti-GD2 antibody (Unituxin (registered trademark)) was not observed to be injured under a microscope against IMR32 in which Spheroid was formed.
- Example 4 ⁇ Confirmation of injury activity to solid tumor mass >> Target IMR32 spheroids were prepared as described in Example 3 and attached to 384 well microplates. Cells of the invention and primary NK were prepared as described in Example 3 and stained with PHK26. The cytotoxicity assay of IMR32 spheroid is performed in 5 groups, in which only the cells of the present invention or primary NK are added, the cells of the present invention or primary NK and anti-GD2 antibody are added, and only anti-GD2 antibody is added. Those not added were prepared as controls.
- cytotoxicity assay After cytotoxicity assay, centrifuge (500 g, 5 min, 4 ° C), remove supernatant, add 7-AAD solution diluted with PBS (Beckman Coulter, A07704), suspend, and incubate at room temperature for 10 min did. Measurements were made using a flow cytometer (BD LSR Fortessa, BD Bioscience) and analyzed with FlowJo software. The cytotoxic activity was calculated by the following formula. The same calculation was performed in the following examples. (Target cell death when incubated with effector cells-natural cell death (negative control)) / (maximum cell death (positive control)-natural cell death (negative control)) x 100
- FIGS. 4A-C The results are shown in FIGS. 4A-C. Regardless of the presence or absence of the anti-GD2 antibody, the cells of the present invention have entered the IMR32 spheroid and have begun to collapse including the central part (lower part of FIG. 4A). Although primary NK is collected on the surface of IMR32 spheroid regardless of the presence of anti-GD2 antibody, it does not penetrate inside, but in the presence of anti-GD2 antibody, it accumulates more in the vicinity of IMR32 spheroid than in the absence. (Fig. 4A middle). The cells of the present invention showed high cytotoxic activity compared to primary NK regardless of the presence or absence of anti-GD2 antibody (FIG. 4C).
- SKOV3 cells a human ovarian cancer cell line introduced with GFP, were cultured in RPMI1640.
- SKOV3 cells GFP-labeled human ovarian cancer cell line, cultured in RPMI1640
- the day of transplantation is designated as day0.
- the cells of the present invention or Primary NK were administered intraperitoneally (ip) at 2.5 ⁇ 10 6 cells / 200 ⁇ L (prepared in PBS) on day 5 (after 5 days).
- hIL-2 (Immense, Shionogi Pharmaceutical Co., Ltd.) was administered at 5,000 IU per animal.
- cells and hIL-2 were not administered after day 0.
- the treatment schedule is shown in FIG.
- mice were euthanized, dissected, the mesentery was photographed with BZ-9000 (Keyence), and GFP positive areas were quantified with ImageJ.
- BZ-9000 Keyence
- GFP positive areas were quantified with ImageJ.
- imaging / analysis conditions are constant (imaging equipment, imaging area, excitation wavelength, exposure time, analysis filtering and threshold) Conducted below.
- Statistical analysis was performed on the quantified data using JMP software. After One-way ANOVA (ANOVA), Tukey-Kramer method (multiple comparison test) was used.
- Results are shown in FIGS. 6A and 6B.
- Tumor nodules were observed in the mesentery of mice treated with no treatment and PrimaryPrimNK, but no tumor nodules were observed in the mesentery of mice administered with the cells of the present invention.
- the total density of all pixels in the GFP-positive region of the mesentery is highest in untreated mice, then high in mice administered Primary NK, and low in mice administered cells of the present invention.
- There was no significant difference between untreated mice and mice administered Primary NK, but between untreated mice and mice administered Primary NK and mice administered cells of the present invention Was significantly different (p ⁇ 0.01).
- ⁇ Improved cell population manufacturing method Cells were prepared as follows to produce three types of cell populations. 1) The cells obtained by the methods 2) and 3) shown below are mixed 1: 1 (hereinafter referred to as “NK-like + mono”). 2) After removing CD2, CD3, CD19, CD19, CD20, CD56, CD66b, CD123, glycophorin A positive cells from PBMC using EasySep TM Human Monocyte Enrichment Kit WITHOUT CD16 DEPLETION (STEMCELL, Cat. 19058), 5 ⁇ 10 5 Suspend in KBM-501 (5% AB Serum) at a density of cells / mL and use Nunc Easy Flask 75 FILIT NUNCLON DSI (Thermo Fisher Scientific, Cat. 156944) or Nunc MULTIDISH 6 NUNCLON DELTA SI (Thermo Fisher Scientific, Cat. 140675) ) For 14 days (hereinafter referred to as “enriched mono”).
- Fig. 7 shows a photograph of cells 10 days after the start of culture.
- two groups other than the enriched Mono group many cells with typical activated lymphocyte-like morphology are confirmed.
- the concentrated Mono group many large and strongly adherent myeloid cells are confirmed, but relatively small cells that are floating can also be confirmed.
- the culture condition is good, the growth in KBM-501 is properly performed, and no conspicuous apoptosis is observed.
- ⁇ Injury activity measurement, CD107a positive rate measurement >> RPMI1640 medium containing 10% FBS (Nichirei Bioscience, 171012-500ML) and 100 units of penicillin, 100 ⁇ g / mL streptomycin (Nacalai Tesque, 26253-84) in K562 cells (human chronic myeloid leukemia cell line) (Pharmaceutical industry, 189-02025) (hereinafter referred to as 10% FBS / RPMI1640) to a concentration of 1 ⁇ 10 6 cells / mL.
- the prepared K562 cells were stained with PKH26 Red Fluorescent Cell Linker Kit (Sigma) to prepare 2 ⁇ 10 6 cells / mL.
- NK-like + mono, enriched NK-like, enriched mono Add one of the above three types of cell population (NK-like + mono, enriched NK-like, enriched mono) and K562 cells to a 96-well plate so that the cell number ratio is 1: 1, and then mix. And reacted at 37 ° C. for 2 hours.
- K562 cells were added to the plate, then 200 ⁇ g / mL of APC-labeled anti-human CD107a antibody * (Biolegend, 328620) was added to a final concentration of 1 ⁇ g / mL, and finally the above 3
- Various cell populations were added.
- FIGS. 8A and B The results are shown in FIGS. 8A and B.
- the NK-like + mono cell population and the enriched NK-like cell population showed high cytotoxic activity.
- CD107a is present in NK cell granules and migrates to the cell membrane surface during degranulation (perforin, granzyme release), so CD107a being positive indicates indirectly that NK has attacked the subject. .
- chemokine receptor expression ⁇ Confirmation of chemokine receptor expression >> Expression of chemokine receptors CCR4, CCR5, CCR6, CXCR3 and CXCR4 in NK-like cells prepared by the improved production method of this example (a production method using a concentrated NK-like cell population and a NK-like + mono cell population) The experiment was conducted according to the procedure described in Example 1. The results are shown in FIG. By the improved production method of this example, a cell population containing CCR5-positive, CCR6-positive and CXCR3-positive cells could be obtained. It was also found that CCR6 expression may vary depending on the donor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
関連出願の相互参照
本出願は、2018年3月27日出願の日本特願2018-59624号の優先権を主張し、その全記載は、ここに特に開示として援用される。
[1]CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞を含む、細胞集団。
[2]上記CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞が、更にCD11a高発現性及びCD11c高発現性であり、高発現性は、末梢血から得た、実質的な培養を行なっていないNK細胞の集団における発現との比較により判断される、[1]に記載の細胞集団。
[3]上記CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞が、更にIntegrin α1陽性、Integrin α3陽性及びIntegrin β3陰性である、[1]又は[2]に記載の細胞集団。
[4]上記細胞集団中、CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞の割合は30%以上である、[1]から[3]のいずれか一に記載の細胞集団。
[5]CD3及びCD19からなる群から選択されるいずれかが陽性である細胞の比率が5%未満である、[1]から[4]のいずれか一に記載の細胞集団。
[6]上記細胞集団において、CD4、CD8、CD14、CD19及びCD36からなる群から選択されるいずれかが陽性である細胞が除去された、[1]から[5]のいずれか一に記載の細胞集団。
[7]固形腫瘍への浸潤に使用するための、[1]から[6]のいずれか一に記載の細胞集団。
[8]固形腫瘍に浸潤している、CCR5陽性、CCR6陽性、CXCR3陽性、Integrin α1陽性、Integrin α3陽性及びIntegrin β3陰性であり且つCD3陰性である細胞。
[9][1]から[7]のいずれか一に記載の細胞集団、および医薬として許容される添加物を含む、医薬組成物。
[10]初代単核球細胞集団を調製する工程と、
初代単核球細胞集団からCD3陽性細胞を除去する工程と、
初代単核球細胞集団から単球及びB細胞からなる群から選択されるいずれかを除去する工程と、
CD3陽性細胞、並びに単球及びB細胞からなる群から選択されるいずれかが除去された残りの細胞集団を、IL-2を含む培地で培養する工程とを含む、
[1]から[7]に定義の細胞集団の製造方法。
本発明は、CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞を含む、細胞集団を提供する。CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞を、「CCR5+/CCR6+/CXCR3+/CD3-細胞」、又は単に「CCR5+/CCR6+/CXCR3+/CD3-」と表す場合がある。表面抗原マーカーの記載について使用する「/」は「及び、且つ」を意味し、例えば「CCR5+/CCR6+/CXCR3+/CD3-」は「CCR5+であり、CCR6+であり、CXCR3+であり、且つCD3-である」の意味である。
CCR5、CCR6及びCXCR3は、ケモカインレセプターである。ケモカイン及びケモカインレセプターは、炎症や免疫応答での細胞遊走、造血幹細胞の骨髄へのホーミングなどに関わる。ケモカインは、白血球、リンパ球、NK細胞、T細胞などを、組織に遊走させるために必要な物質であり、ケモカインレセプターは、細胞の表面でケモカインを受けとめ、細胞内へ各種シグナルを伝達する。
本発明により提供されるCCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞を含む細胞集団は、該CCR5+/CCR6+/CXCR3+/CD3-細胞がCD11c高発現性であることができる(CCR5+/CCR6+/CXCR3+/CD3-/CD11chigh)。CD11cは、integrin αXとしても知られている細胞接着分子である。CD11cは、単球、マクロファージ、顆粒球、ミエロイド系樹状細胞に発現することが知られている。CD11cは、CD18と結合して、細胞接着などに関与することが知られている。
CCR5+/CCR6+/CXCR3+/CD3-/ Integrin α1high/Integrin α3high/Integrin α4high/Integrin α5high/ICAM-1high/Integrin β1high細胞の集団であることができる。
本発明により提供されるNK様細胞の集団は、腫瘍部位への上昇した走化性を持つことができる。また、本発明により提供されるNK様細胞の集団は、腫瘍塊に浸潤することができる。腫瘍塊への浸潤とは、腫瘍塊の内部に細胞(例えば、免疫細胞)が侵入している状態を意味する。
加えて、スフェロイドに対する細胞傷害活性は、末梢血から得た実質的な培養を行なっていないNK細胞に比較して、本発明により提供されるNK様細胞の集団では、非常に高かった。また、スフェロイドに対する細胞傷害活性は、本発明により提供されるNK様細胞の集団と抗体を併用した系と抗体を併用しない系の両系において、有意差はなかった。
(エフェクター細胞と共培養した場合の細胞死-自然細胞死(陰性コントロール))/(最大細胞死(陽性コントロール)-自然細胞死(陰性コントロール))×100
本発明により提供されるCCR5+/CCR6+/CXCR3+/CD3-NK様細胞の集団は、in vivoでの固形腫瘍に対する治療効果を有することができる。
本発明は、初代単核球細胞集団を調製する工程と、初代単核球細胞集団からCD3陽性細胞を除去する工程と、初代単核球細胞集団から単球及びB細胞からなる群から選択されるいずれかを除去する工程と、当該CD3陽性細胞、並びに単球及びB細胞からなる群から選択されるいずれかが除去された残りの細胞集団を、IL-2を含む培地で培養する工程とを含む、CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞の集団の製造方法を提供する。
本発明の製造方法において、初代単核球細胞集団は、被験者から採取された血球細胞から単核球を分離する工程によって得ることができる。血球細胞は、末梢血、臍帯血、骨髄およびリンパ節からなる群から選択されるいずれかから採取される場合がある。血球細胞は末梢血からアフェレーシス法により採取される場合がある。培養前の初代単核球細胞集団は、CCR5+/CCR6+/CXCR3+/CD3-細胞を含まないものであることができる。
本発明の製造方法において、初代単核球細胞集団からCD3陽性細胞を除去する工程により、T細胞及び/又はNKT細胞を除去することができる場合がある。T細胞の除去は、CD3陽性細胞のほか、CD4陽性細胞及びCD8陽性細胞から選択される1種、又は2種を除去する工程によって達成される場合がある。また、本発明の製造方法において、初代単核球細胞集団から単球及びB細胞からなる群から選択されるいずれかを除去する工程について、単球の除去は、CD14陽性細胞、CD36陽性細胞、及びHLA-DR陽性細胞から選択される1種、2種、又は3種の細胞を除去する工程によって達成される場合がある。B細胞の除去は、CD19陽性細胞及びCD20陽性細胞から選択される1種又は2種の細胞を除去する工程によって達成される場合がある。
本発明のNK様細胞の製造方法は、初代単核球細胞集団から赤血球及び赤芽球系前駆細胞を除去する工程を含む場合がある。赤血球及び赤芽球系前駆細胞を除去する工程は、glycophorin A陽性細胞を除去する工程によって達成される場合がある。
初代単核球細胞集団からCD3陽性細胞、並びに単球及びB細胞からなる群から選択されるいずれかが除去された残りの細胞集団を培養するために用いる細胞培養用培地は、KBM501培地(コージンバイオ株式会社。IL-2を1,750JRU/ml含む。ヒトNK細胞Primary Culture用)、CellGro SCGM培地(セルジェニックス、岩井化学薬品株式会社)、X-VIVO15培地(ロンザ、タカラバイオ株式会社)、コスメディウム008 (コスモバイオ。IL-2を1,750JRU/ml含む。ヒトNK細胞Primary Culture用)、CTS AIM V Medium GibcoTM CTSTM AIM VTM Medium(サーモフィッシャーサイエンティフィック。T細胞および樹状細胞を増殖・操作するための既知組成の無血清培地)、CTS OpTmizer T Cell Expansion Basal Medium(サーモフィッシャーサイエンティフィック。ヒトTリンパ球の成長および増殖用)、IMDM、MEM、DMEM、RPMI-1640等を含むが、これらに限定されない。
培地の交換又は添加もしくは補充は、所望の細胞数のNK様細胞が得られることを条件として、培養開始後いつ行われてもかまわないが、3~5日毎が好ましい。
本発明は、NK様細胞の集団、および医薬として許容される添加物を含む、医薬組成物を提供する。医薬として許容される添加物としては、例えば等張化剤、pH調整剤、緩衝剤、安定化剤、凍結保護剤、抗生物質等を例示できる。具体的には、水、エタノール、塩化ナトリウム、ブドウ糖、アルブミン等が挙げられる。本発明の医薬組成物に含まれるNK様細胞の集団は、上記の、本発明によって提供されるCCR5+/CCR6+/CXCR3+/CD3-NK様細胞の集団であることが好ましい。また本発明の医薬組成物に含まれる細胞集団は、腫瘍細胞傷害活性が高いNK様細胞の集団であることが好ましく、固形腫瘍に浸潤するNK様細胞の集団であることがより好ましい。
本発明は、患者に治療的有効量のNK様細胞の集団を投与する工程を含む、患者の固形腫瘍の治療及び予防のための方法を提供する。本発明のNK様細胞の集団は、固形腫瘍の腫瘍細胞を傷害することができるため、患者の固形腫瘍の治療及び予防に有用である。
本発明は、上記治療用途又は研究用途における使用のためのキットを提供する。キットは、バック、バイアル及びチューブなど1つ又は複数の容器を含むことができる。容器は、本発明により提供される細胞集団を、任意選択により医薬として許容される添加物とともに含む医薬組成物として含むことができる。キットは、本発明により提供される細胞の集団を含む容器を、別の薬剤又は抗体医薬品との組合せで含むことができる。キットは、任意選択により、本明細書に記載する治療用途又は研究用途に関するラベル又は説明書とともに細胞集団を含む。
<<ケモカインレセプターの発現確認>>
健常人ボランティアの末梢血を比重遠心により分離し、末梢血単核球(以下、PBMC)を得た。PBMCから、CliniMACS CD3(ミルテニーバイオテック社, カタログ番号130-017-601)を1×107細胞あたり5μL使用してCD3陽性細胞を除去し(ここで回収した細胞を「Primary NK」と表す)、残りの細胞を培養した。培養は、細胞を5×105細胞/mLの密度でKBM-501(コージンバイオ、5% AB Serum添加)に懸濁し、6ウェルプレート(サーモフィッシャーサイエンティフィック, 140675)または、T-75フラスコ(サーモフィッシャーサイエンティフィック, 156499)を用いて14日間培養(9日目に培地添加)した。この細胞集団の細胞を、「14日間培養細胞」及び「本発明の細胞」と表す。
一般にCCR5、CCR6、CXCR3はMDSC(Myeloid-derived suppressor cells)やTregといった免疫抑制性の細胞集団が持ち、これらの細胞は生体内ではCold tumorと呼ばれる状態の腫瘍組織に多く存在することが知られる。本発明の細胞はこれらと同様の走化性を持つことが考えられることから、免疫治療が極めて奏功しにくいとされるCold tumorにも効率よく浸潤し、傷害が可能であることが想定される。
細胞接着分子群の解析には、実施例1と同様に14日間培養した本発明の細胞、及びコントロールとしてPrimary NKを使用した。フローサイトメトリー法により解析を行った。蛍光標識に用いた抗体を表2に記載する。蛍光標識は、上記と同様の手順で行った。
腫瘍組織への浸潤には、血管外への漏出に続き間質の通過、腫瘍細胞塊への接着並びに侵入といった複数の要所での細胞同士の接着あるいは細胞外マトリックスとの接着が必要になり、本発明で得られた細胞はそのいずれをも可能とする接着分子発現パターンを有するものと考えられる。
<<CD3陽性細胞及びCD19陽性細胞の含有率>>
CD3陽性細胞及びCD19陽性細胞の含有率を解析するため、実施例1と同様に14日間培養した本発明の細胞を使用し、コントロールとしてはPBMCを使用した。蛍光標識に用いた抗体は、PE標識抗ヒトCD3抗体(Biolegend, 300408)及びPerCP-Cy5.5標識抗ヒトCD19抗体(Biolegend, 302230)である。蛍光標識は、実施例1と同様の手順で行った。
結果を図2に示す。14日間培養した本発明の細胞に含まれるCD3陽性細胞は0.025%であり、CD19陽性細胞は0.28%であった。一方で、培養をしていないPBMCに含まれるCD3陽性細胞は64.7%であり、CD19陽性細胞は8.57%であった。
<<固形腫瘍塊への浸潤確認>>
IMR32 spheroidを標的として、本発明の細胞の浸潤を観察した。
IMR32細胞(ヒトMYCN増幅神経芽腫細胞株)をトリプシンEDTAにより剥離し、RPMI(10% FBS)にて100μL中3×103細胞となるように調製し、EZ-Bind Shut II(登録商標)マイクロプレート(IWAKI, Cat. 4870-800LP)に播種し、37℃で48~72時間培養してIMR32 spheroidを形成させた。IMR32 spheroidは、384ウェルマイクロプレート(フィルムボトム、ハイコンテントイメージング用)(CORNING, Cat. 4518)に200μLチップを用いて1ウェルあたり1個を移植し、37℃で1~2時間程度インキュベーションして底面に接着させた。
<<固形腫瘍塊への傷害活性確認>>
標的のIMR32 spheroidは、実施例3に記載のとおり調製し、384ウェルマイクロプレートに付着させた。本発明の細胞及びprimary NKは、実施例3に記載のとおり調製し、PHK26染色した。IMR32 spheroidの細胞傷害アッセイは、本発明の細胞又はprimary NKのみ添加、本発明の細胞又はprimary NKと抗GD2抗体を添加、抗GD2抗体のみ添加の5群で行い、エフェクター細胞も抗GD2抗体も添加しないものを対照(コントロール)として用意した。本発明の細胞又はprimary NKは、IMR32 spheroidを付着させた384ウェルマイクロプレートの1ウェルにつき、1×104細胞/20μL(KBM-501, 5% AB Serum)を添加した。抗GD2抗体は、dinutuximab (UnituxinTM、UnitedTherapeutics社)を使用し、終濃度10μg/mLとなるようにMR32 spheroidを付着させた384ウェルマイクロプレートに添加した。細胞傷害アッセイは37℃で21時間インキュベーションすることにより行った。
細胞傷害活性は、次式で計算した。なお、以下の実施例でも同様に計算した。
(エフェクター細胞とインキュベートした場合の標的細胞の細胞死-自然細胞死(陰性コントロール))/(最大細胞死(陽性コントロール)-自然細胞死(陰性コントロール))×100
本発明の細胞は、抗GD2抗体の有無にかかわらず、primary NKと比較して、高い細胞傷害活性を示した(図4C)。
<<in vivo固形腫瘍モデルによる治療効果確認>>
GFP導入されたヒト卵巣がん細胞株であるSKOV3細胞を、RPMI1640で培養した。6~7週齢のNOGマウスの腹腔内に、SKOV3細胞(GFP標識されたヒト卵巣がん細胞株、RPMI1640で培養)を1×105細胞/200μL(PBSで調製)で移植した。移植した日をday0とする。その後、day5(5日後)に本発明の細胞またはPrimary NKを2.5×106細胞/200μL(PBSで調製)で、腹腔内(i.p.)投与した。また、day5, 6, 7にはhIL-2(イムネース、シオノギ製薬株式会社)を1頭あたり5,000IU投与した。コントロール群にはday0以降、細胞およびhIL-2の投与を行わなかった。治療スケジュールを図5に示す。
<<細胞集団の改良製造方法>>
以下のとおり、細胞を調製し、3タイプの細胞集団を作製した。
1) 以下に示す2) および3) の方法で得られる細胞を1:1で混合したもの(以下、「NK様+mono」と表す)。
2) PBMCからEasySepTM Human Monocyte Enrichment Kit WITHOUT CD16 DEPLETION(STEMCELL, Cat. 19058)を使用してCD2, CD3, CD19, CD20, CD56, CD66b, CD123, glycophorin A陽性細胞を除去後、5×105細胞/mLの密度でKBM-501(5% AB Serum)に懸濁し、Nunc Easy Flask 75 FILIT NUNCLON DSI(Thermo Fisher Scientific, Cat. 156944)もしくはNunc MULTIDISH 6 NUNCLON DELTA SI(Thermo Fisher Scientific, Cat. 140675)にて14日間培養したもの(以下、「濃縮mono」と表す)。
K562細胞(ヒト慢性骨髄性白血病細胞株)を10%FBS(ニチレイバイオサイエンス, 171012-500ML)および100ユニットのペニシリン、100μg/mLのストレプトマイシン(ナカライテスク, 26253-84)を含むRPMI1640培地(和光純薬工業, 189-02025)(以下、10%FBS/RPMI1640とする)にて1×106細胞/mLの濃度に調製した。調製したK562細胞に、PKH26 Red Fluorescent Cell Linker Kit(Sigma)を用いて染色し、2×106細胞/mLとなるように調製した。
結果を、図8A及びBに示す。NK様+mono細胞集団及び濃縮NK様細胞集団が、高い細胞傷害活性を示した。
※:CD107aはNK細胞内顆粒に存在し、脱顆粒(パーフォリン、グランザイム放出)時に細胞膜表面上に移行するので、CD107aが陽性であるということは、対象をNKが攻撃したことを間接的に示す。
本実施例の改良製造方法(濃縮NK様細胞集団、及びNK様+mono細胞集団を材料とする製造方法)で作成したNK様細胞における、ケモカインレセプターCCR4、CCR5、CCR6、CXCR3及びCXCR4の発現について、実施例1に記載の手順で実験を行った。
結果を図9に示す。本実施例の改良製造方法により、CCR5陽性、CCR6陽性及びCXCR3陽性の細胞を含む細胞集団を得ることができた。また、ドナーにより、CCR6の発現性が異なる場合があることが分かった。
Claims (10)
- CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞を含む、細胞集団。
- 前記CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞が、更にCD11a高発現性及びCD11c高発現性であり、高発現性は、末梢血から得た、実質的な培養を行なっていないNK細胞の集団における発現との比較により判断される、請求項1に記載の細胞集団。
- 前記CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞が、更にIntegrin α1陽性、Integrin α3陽性及びIntegrin β3陰性である、請求項1又は2に記載の細胞集団。
- 前記細胞集団中、CCR5陽性、CCR6陽性及びCXCR3陽性であり且つCD3陰性である細胞の割合は30%以上である、請求項1から3のいずれか一項に記載の細胞集団。
- CD3及びCD19からなる群から選択されるいずれかが陽性である細胞の比率が5%未満である、請求項1から4のいずれか一項に記載の細胞集団。
- 前記細胞集団において、CD4、CD8、CD14、CD19及びCD36からなる群から選択されるいずれかが陽性である細胞が除去された、請求項1から5のいずれか一項に記載の細胞集団。
- 固形腫瘍への浸潤に使用するための、請求項1から6のいずれか一項に記載の細胞集団。
- 固形腫瘍に浸潤している、CCR5陽性、CCR6陽性、CXCR3陽性、Integrin α1陽性、Integrin α3陽性及びIntegrin β3陰性であり且つCD3陰性である細胞。
- 請求項1から7のいずれか一項に記載の細胞集団、および医薬として許容される添加物を含む、医薬組成物。
- 初代単核球細胞集団を調製する工程と、
初代単核球細胞集団からCD3陽性細胞を除去する工程と、
初代単核球細胞集団から単球及びB細胞からなる群から選択されるいずれかを除去する工程と、
前記CD3陽性細胞、並びに単球及びB細胞からなる群から選択されるいずれかが除去された残りの細胞集団を、IL-2を含む培地で培養する工程とを含む、
請求項1から7に定義の細胞集団の製造方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019242949A AU2019242949B2 (en) | 2018-03-27 | 2019-03-26 | Population of cd3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same |
EP19775565.5A EP3786287A4 (en) | 2018-03-27 | 2019-03-26 | POPULATION OF CD3 NEGATIVE CELLS EXPRESSING A CHEMOKINE RECEPTOR AND A CELL ADHESION MOLECULE, AND APPLICATION AND METHOD OF MAKING THEREOF |
CN201980022253.XA CN111918963B (zh) | 2018-03-27 | 2019-03-26 | 表达趋化因子受体和细胞粘附分子的cd3阴性细胞群体及其用途和制备方法 |
US17/041,061 US11987812B2 (en) | 2018-03-27 | 2019-03-26 | Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same |
KR1020207030870A KR102534472B1 (ko) | 2018-03-27 | 2019-03-26 | 케모카인 리셉터와 세포 접착 분자를 발현하는 cd3 음성 세포의 집단, 및 그 이용 그리고 그 제조 방법 |
AU2022291532A AU2022291532A1 (en) | 2018-03-27 | 2022-12-22 | Population of cd3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018059624A JP6543375B1 (ja) | 2018-03-27 | 2018-03-27 | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用 |
JP2018-059624 | 2018-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019189115A1 true WO2019189115A1 (ja) | 2019-10-03 |
Family
ID=67212257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/012744 WO2019189115A1 (ja) | 2018-03-27 | 2019-03-26 | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用並びにその製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11987812B2 (ja) |
EP (1) | EP3786287A4 (ja) |
JP (1) | JP6543375B1 (ja) |
KR (1) | KR102534472B1 (ja) |
CN (1) | CN111918963B (ja) |
AU (2) | AU2019242949B2 (ja) |
TW (2) | TW202336229A (ja) |
WO (1) | WO2019189115A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3884041A2 (en) * | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
JP6977969B2 (ja) | 2019-03-22 | 2021-12-08 | 株式会社ガイアバイオメディシン | 免疫細胞提供システム |
JP2021136883A (ja) | 2020-03-02 | 2021-09-16 | 株式会社ガイアバイオメディシン | 高活性nk細胞の処理方法 |
JP7411485B2 (ja) | 2020-04-02 | 2024-01-11 | アズビル株式会社 | センサシステム及び電磁波照射装置 |
AU2021301788A1 (en) | 2020-06-30 | 2023-01-19 | Gaia Biomedicine Inc. | Method for stabilizing binding of NK cell and antibody, and use thereof |
CN118103492A (zh) | 2021-09-08 | 2024-05-28 | 盖亚生物制药有限公司 | 细胞的处理方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013027385A (ja) | 2011-06-24 | 2013-02-07 | Kyushu Univ | Nk細胞の増幅方法 |
JP2013515497A (ja) | 2009-12-29 | 2013-05-09 | ガミダ セル リミテッド | ナチュラルキラー細胞の増殖および活性の強化方法 |
JP2018059624A (ja) | 2016-08-22 | 2018-04-12 | ジョンソン エレクトリック ソシエテ アノニム | リングギア及び歯車装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
-
2018
- 2018-03-27 JP JP2018059624A patent/JP6543375B1/ja active Active
-
2019
- 2019-03-26 WO PCT/JP2019/012744 patent/WO2019189115A1/ja unknown
- 2019-03-26 AU AU2019242949A patent/AU2019242949B2/en active Active
- 2019-03-26 CN CN201980022253.XA patent/CN111918963B/zh active Active
- 2019-03-26 EP EP19775565.5A patent/EP3786287A4/en active Pending
- 2019-03-26 KR KR1020207030870A patent/KR102534472B1/ko active IP Right Grant
- 2019-03-26 US US17/041,061 patent/US11987812B2/en active Active
- 2019-03-27 TW TW112119612A patent/TW202336229A/zh unknown
- 2019-03-27 TW TW108110602A patent/TW202003837A/zh unknown
-
2022
- 2022-12-22 AU AU2022291532A patent/AU2022291532A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013515497A (ja) | 2009-12-29 | 2013-05-09 | ガミダ セル リミテッド | ナチュラルキラー細胞の増殖および活性の強化方法 |
JP2013027385A (ja) | 2011-06-24 | 2013-02-07 | Kyushu Univ | Nk細胞の増幅方法 |
JP5572863B2 (ja) | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Nk細胞の増幅方法 |
JP2018059624A (ja) | 2016-08-22 | 2018-04-12 | ジョンソン エレクトリック ソシエテ アノニム | リングギア及び歯車装置 |
Non-Patent Citations (19)
Title |
---|
BERAHOVICH R.D. ET AL.: "Evidence for NK cell subsets based on chemokine receptor expression", J. IMMUNOL., vol. 177, no. 11, 1 December 2006 (2006-12-01), pages 7833 - 7840, XP055638851 * |
DORONIN ET AL., BMC CANCER, vol. 14, 2014, pages 295 |
FRANCISZKIEWICZ K ET AL., CANCER RES, 2012 |
GONZAELEZ-MARTIN A ET AL., ONCOIMMUNOLOGY, 2012 |
HIRSCHHAEUSER F ET AL., J. BIOTECHNOL., vol. 148, no. 1, 1 July 2010 (2010-07-01), pages 3 - 15 |
JENA B ET AL., BLOOD, vol. 116, 2018, pages 1035 - 1044 |
LEVI I. ET AL.: "Characterization of tumor infiltrating natural killer cell subset", ONCOTARGET, vol. 6, no. 15, 23 March 2015 (2015-03-23) - 30 May 2015 (2015-05-30), pages 13835 - 13843, XP055638853 * |
LIMA M ET AL., JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2015, pages 18 |
MAENPAA ET AL., INT. J. CANCER, vol. 53, 1993, pages 850 - 855 |
MELERO I. ET AL., CANCER DISCOVERY, vol. 4, 2014, pages 522 - 526 |
MILOTTI E.CHIGNOLA R., PLOS ONE, vol. 5, no. 11, 2010, pages e13942 |
MOON E ET AL., CLIN. CANCER RES., vol. 17, no. 14, 2011, pages 4719 - 4730 |
NAGARSHETH N ET AL., NAT. REV. IMMUNOL., 2017 |
POLI A. ET AL.: "CD 56bright natural killer (NK) cells: an important NK cell subset", IMMUNOLOGY, vol. 126, no. 4, 2009, pages 458 - 465, XP002536329 * |
SACKSTEIN R. ET AL., LAB. INVEST., 2017 |
SAITO S. ET AL.: "Ex Vivo generation of highly purified and activated natural killer cells from human peripheral blood. Hum", GENE THER. METHODS, vol. 24, no. 2, 2013, pages 241 - 252, XP055154762, doi:10.1089/hgtb.2012.183 * |
See also references of EP3786287A4 |
TAKAHASHI E. ET AL.: "Induction of CD 16+ CD 56bright NK cells with antitumour cytotoxicity not only from CD 16- CD 56bright NK cells but also from CD 16- CD 56dim NK cells", SCAND. J. IMMUNOL., vol. 65, no. 2, 2007, pages 126 - 138, XP002528954, doi:10.1111/j.1365-3083.2006.01883.x * |
XIANG X ET AL., PLOS ONE, vol. 6, no. 1, 2011, pages e14640 |
Also Published As
Publication number | Publication date |
---|---|
AU2019242949B2 (en) | 2022-09-29 |
JP6543375B1 (ja) | 2019-07-10 |
JP2019170176A (ja) | 2019-10-10 |
EP3786287A4 (en) | 2022-01-12 |
TW202003837A (zh) | 2020-01-16 |
TW202336229A (zh) | 2023-09-16 |
AU2022291532A1 (en) | 2023-02-02 |
CN111918963B (zh) | 2024-04-23 |
KR102534472B1 (ko) | 2023-05-19 |
CN111918963A (zh) | 2020-11-10 |
KR20200135514A (ko) | 2020-12-02 |
AU2019242949A1 (en) | 2020-11-19 |
US11987812B2 (en) | 2024-05-21 |
US20210095250A1 (en) | 2021-04-01 |
EP3786287A1 (en) | 2021-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019189115A1 (ja) | ケモカインレセプターと細胞接着分子を発現するcd3陰性細胞の集団、およびその利用並びにその製造方法 | |
JP5572863B2 (ja) | Nk細胞の増幅方法 | |
CN110603320B (zh) | 高活性nk细胞及其应用 | |
JP2019501956A (ja) | 免疫療法に使用するための組成物 | |
US20240101960A1 (en) | Expansion and use of expanded nk cell fractions | |
JP5989016B2 (ja) | Nk細胞の増幅方法 | |
TWI757709B (zh) | 含有nk細胞之細胞集團之製造方法 | |
JPWO2009145238A1 (ja) | 免疫調節剤及びその利用 | |
WO2005054459A1 (ja) | 造血幹細胞あるいは血管内皮前駆細胞の製造方法 | |
JP6697611B2 (ja) | 高活性nk細胞、およびその利用 | |
KR102032384B1 (ko) | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 | |
JP2020108405A (ja) | 高活性nk細胞、およびその利用 | |
TWI846668B (zh) | 高活性nk細胞及其利用 | |
WO2020152661A1 (ja) | Nk細胞を含む細胞集団の製造方法 | |
JP2023153286A (ja) | Nk細胞を含む細胞集団の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19775565 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207030870 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019775565 Country of ref document: EP Effective date: 20201027 |
|
ENP | Entry into the national phase |
Ref document number: 2019242949 Country of ref document: AU Date of ref document: 20190326 Kind code of ref document: A |